Your Gateway to World-
Class CDMO Solutions
From bench to bedside, lab to lives, the Taiwan CDMO Alliance (TCA)
unites the strengths of 17 well-established CDMOs to deliver integrated, cost-efficient, and innovative solutions for global drug development and manufacturing.
Our Track Record
$7.8B
Combined Market Cap
300+
DMF Submitted
800+
CDMO Projects Delivered
0 OAI
Since 2015
20+
Years QA Experience
ABOUT TCA
Making Taiwan Your Partner for Innovation
The Taiwan CDMO Alliance (TCA) is an industry alliance founded by 17 CDMOs under the mission of providing integrated services with comprehensive capabilities.
Unparalleled One-Stop-Shop Experience
With decades of global CDMO expertise, TCA represents one of the world's most mature and comprehensive ecosystems for expediting innovation to patients.
Strategic Hub Location
Located at the heart of Asia, TCA offers proximity to major global markets with seamless supply chain integration and scalable capacity ensuring world-class quality.
SERVICE & CAPABILITIES
The Full Bloom of Our Capabilities
Peptide
Linker/
Payload
Cytotoxic
Drug
Substance
Hormone
ADC/XDC
Multispecific antibodies
Nucleotide
Steroid
Lyophyilizaion
Ophthaimic
Injectable
Lipid Formulation
Drug
Product
Semi-solid
Suspension
Oral Solid
Soft-Gel
Pre-Clinical
Alt Source
Lead
Optimization
Life
Cycle
Validation
Phase 1
Phase 2
Phase 3
Commercialization
WORKING WITH TCA
The 6Cs of TCA Promise
1
Comprehensive
From Preclinical to Commercialization. Small Molecules, Biologics, Peptides, ADC, Solid Oral, Injectable, Lyophilized, Pre-filled Syringe, Ophthalmic, Topical, and more.​
2
Competitiveness
High barrier technologies: Cytotoxic, Steroid, Nano Technology, Spray Dried, Semi-Synthetic. High level of educated workforce.​
​
3
Capacities
Flexibility due to highly developed and cooperative network of domestic suppliers. Rapid scalability and accelerated timelines.​
​
4
Compliance
Maintains Zero Official Action Indicated (OAI) status with FDA. Deep-rooted compliance culture with major global regulatory bodies.
​
5
Cost
Competitive pricing without compromising quality. Equivalent to other Asian providers.​
​
​
6
Care
Customer loyalty and respect for IP. Seamless handoffs for multi-step manufacturing.
​
​
OUR PROCESS
Working Side by Side for Your Project Success
Connect & Screen
-
Network Outreach
-
Needs & Requirements
-
Preliminary Due Diligence
Common Questions
What types of projects does TCA support?
TCA is built for innovators who need end-to-end CMC support for complex or technically challenging projects, including biologics, ADCs, high-potency and cytotoxic APIs, nano-formulations, advanced oral delivery systems, and sterile injectables, from preclinical through commercial scale.
What can I expect from a TCA partnership?
TCA emphasizes quality, integrity, respect for IP, transparency, customer loyalty, and urgency in solving problems. The alliance is designed to be both technically sophisticated and highly customer-centric.
What is TCA's role in my project?
TCA acts as a single business development interface. Its BD team listens to your needs, screens across the 17 members, and connects you with the most suitable partners, so you don't have to search and qualify dozens of CDMOs on your own.
What problem does TCA solve for biotech and pharma companies?
Finding a reliable CDMO partner and building a resilient supply chain takes time and carries risk. TCA provides a single, trusted entry point into a mature CDMO ecosystem, enabling you to quickly identify suitable partners, access advanced technologies, and reduce risks related to capacity, quality, and supply-chain continuity.
Why is Taiwan a strategic base for CDMO partnerships?
TCA members form a tightly clustered CDMO ecosystem in Taiwan, located at the heart of Asia and within a few hours of major cities like Tokyo, Seoul, Shanghai, and Hong Kong. This geographic concentration enables seamless supply-chain integration, efficient logistics, and scalable capacity across multiple sites.
What experience and track record do TCA members have?
Collectively, TCA members bring decades of CDMO experience with $7.8B+ USD combined market cap, 300+ drug substance DMFs, 800+ CDMO projects delivered, and more than 80 commercialized products. The alliance has completed 117 GMP inspections with an excellent compliance record. Member products are supplied to all major regions worldwide.
Who is behind TCA?
TCA operates as an industry alliance under Taiwan BIO (TBIO). TBIO supports the members' joint business development and global marketing efforts by helping them present a unified face to international partners.
What is the Taiwan CDMO Alliance (TCA)?
TCA is an alliance of 17 well-established CDMOs in Taiwan that work together to support drug developers from early R&D through to commercial manufacturing. The members cover both drug substance and drug product across small molecules, biologics, peptides, ADCs, and more.